Stock Analysis
Cytokinetics, Incorporated (CYTK) Stock Analysis
Cytokinetics, Incorporated (CYTK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Cytokinetics, Incorporated (CYTK) currently has an AIQ Score of 40/100, indicating a bearish setup. Risk is the strongest factor at 56/100. Momentum is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CYTK at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $56.13 |
| AIQ Score | 40/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $7.8B |
| P/E Ratio (TTM) | -9.31 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$1.37 |
| Revenue (Q3 FY2026) | $47.56M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.01 |
| Volume | 1.01M |
| 52-week range | $53.55-$88.31 |
| RSI 14 | 38.17 |
| 50-Day SMA | $64.11 |
| 200-Day SMA | $69.78 |
| Analyst Price Target | $99.33 |
| Next Earnings | Feb 23, 2027 |
CYTKCytokinetics, Incorporated
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum28
- Value41
- Quality46
- Risk resilience56
- Sentiment—
CYTK Stock Analysis Summary
Cytokinetics, Incorporated (CYTK) currently has an AIQ Score of 40/100, indicating a bearish setup. Risk resilience is the strongest factor at 56/100. Momentum is the weakest current factor at 28/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, CYTK has AIQ Score of 40/100 with Risk resilience base of 56/100 and fading Momentum at 28/100. Wait for component alignment before adding exposure.
Risk resilience (56/100) leads while Momentum (28/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.05% stock move · CYTK classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CYTK Bullish or Bearish Right Now?
CYTK currently has a bearish overall setup. Risk Resilience is the strongest factor at 56/100, while Momentum is weakest at 28/100. The current evidence suggests a bearish setup.
- - Analyst target implies +76.97% upside from the latest quote.
- - Value is the current constraint at 41/100.
- - Momentum is weak at 28/100.
- - Price is -19.56% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (38 vs 0).
Current Consensus
CYTK's Technical Analysis Consensus is currently Strong Sell, with 0 buy, 8 neutral, and 38 sell votes. CYTK's 14-day RSI is 38.17, which places the stock in a weaker momentum range. CYTK's beta is 1.01, indicating market sensitivity broadly in line with the market.
What Changed in CYTK?
The largest recent change in CYTK is Momentum moving down by 5.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the CYTK Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CYTK Decision Framework
Public evidence layers, setup checks, and risk context for Cytokinetics, Incorporated.
Cytokinetics, Incorporated (CYTK) Stock Analysis
Cytokinetics, Incorporated has an AIQ Score of 40/100 in a Bearish regime. Risk is strongest at 56/100. Beta is 1.01, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CYTK is in a Bearish AIQ regime with score 40/100. |
| Signal Conflict | The primary conflict is that risk leads at 56/100 while momentum lags at 28/100. |
| Factor Evidence | Momentum 28/100 · Value 41/100 · Quality 46/100 · Risk 56/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 56/100.
Momentum is 28/100 and RSI (14) is 38.2.
CYTK is in a Bearish regime at 40/100.
Risk factor is 56/100 with beta 1.01 and annual volatility 43.65%.
Current conflict: risk leads at 56/100 while momentum lags at 28/100.
CYTK Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CYTK Fundamentals
CYTK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CYTK Technical Analysis
CYTK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CYTK Stock Catalysts
Track CYTK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CYTK Dividend Analysis
CYTK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CYTK Financial Data
CYTK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CYTK Risk Analysis
CYTK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CYTK Stock News
CYTK stock news, market tone, recent headlines, and catalyst context.
CYTK vs Biotechnology Peers
Current peer cohort: CYTK · DFTX · DNTH · DYN · ELVN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CYTK Current stock | 40/100 | 41/100 | 28/100 | 56/100 | -0.23 | 43.65% | Current |
| DFTX Definium Therapeutics, Inc. | 59/100 | — | 64/100 | 44/100 | 1.61 | 77.71% | CYTK vs DFTX |
| DNTH Dianthus Therapeutics, Inc. | 56/100 | — | 58/100 | 58/100 | 1.82 | 59.79% | CYTK vs DNTH |
| DYN Dyne Therapeutics, Inc. | 48/100 | — | 52/100 | 42/100 | 0.11 | 63.89% | CYTK vs DYN |
| ELVN Enliven Therapeutics, Inc. | 71/100 | — | 66/100 | 56/100 | 1.43 | 78.19% | CYTK vs ELVN |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for CYTK: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CYTK
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CYTK
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CYTK Stock FAQ
What is CYTK stock price today?
Cytokinetics, Incorporated's current stock price is $56.13. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CYTK bullish or bearish right now?
CYTK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CYTK's market cap?
CYTK's market cap is $7.8B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CYTK's current P/E ratio?
CYTK's current P/E ratio is -9.31 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CYTK's RSI?
CYTK's 14-day RSI is 38.17 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CYTK above its 50-day and 200-day moving averages?
CYTK is -12.45% from its 50-day SMA and -19.56% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CYTK's next earnings date?
CYTK's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CYTK pay a dividend?
CYTK's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.